We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Sanyou Biopharmaceuticals is a CRO company featuring phage display antibody libraries of trillion capacity and offering integrated solutions for innovative antibody drugs that include antibody discovery, efficacy validations and CMC. Currently, the company has 240+ employees, R&D laboratories of 11000 m2 and 300+ clients and partners all around the world.
Established in 2004, LARVOL combines the best of artificial and human intelligence to deliver expertly curated and personalized data solutions to medical affairs, competitive intelligence, commercial, and R&D teams within the pharmaceutical and biotech industry.
PHC Group develops, manufactures, sells, and services across diabetes management, diagnostics and life sciences, as well as healthcare service businesses. Committed to its corporate mission, “We contribute to the health of society through our diligent efforts to create healthcare solutions that have a positive impact and improve the lives of people,” the company offers value-added products and services to customers in over 125 countries.
Epredia is a global precision cancer diagnostics company working to improve patient outcomes by providing groundbreaking technologies. Since our humble beginnings in 1937, every product developed has been impacted by generations of employees who are committed to improving lives by enabling pathologists through enhancing precision cancer diagnostics
ANGLE has worked towards, and received in 2022, US Food and Drug Administration (FDA) clearance for their Parsortix ® PC1 System for use with metastatic breast cancer (MBC) patients. This marks a significant achievement as the first ever FDA cleared product for harvesting circulating tumour cells from MBC patient blood samples for user-validated subsequent analysis. Creating new possibilities in the era of personalised cancer medicine, with the ability to repeat a non-invasive liquid biopsy.
With over 15 years of experience in genetic and epigenetic clinical research, EpigenDx offers high quality products and laboratory services focused on DNA methylation analysis, gene expression profiling, and mutation analysis. Our scientific teams carefully evaluate each project and establish analysis procedures using best fit technologies, including NGS, Pyrosequencing, RT-PCR, digital PCR, and GeneChip Microarray. Our popular services include Line-1 global methylation tests and Foxp3-TSDR analysis for epigenetic immunotherapy. Our GLP compliant and CLIA certified services make us the perfect partner during pre-clinical research and diagnostic test development.
PromoCell is the premier manufacturer of cell culture products. PromoCell offers broad range of human primary cells, stem cells and blood cells, optimized cell culture media, and a comprehensive line of cell biology research products. Our cell culture products provide scientists with physiologically accurate models, and therefore enable them to obtain better research results. As the original manufacturer, PromoCell is committed to the highest possible ethical and legal standards
TransCure bioServices (TCS) provides predictive in vivo pharmacology expertise for drug pre-clinical candidate selection in the fields of infectious, cancer (IO, PDX), inflammation, vaccine and immune disease areas. We are the only preclinical CRO providing commercially HIV, immuno-oncology (IO) therapy, PDX, IBD, vaccine and autoimmune mouse models with a fully functional reconstituted HUMAN IMMUNE SYSTEM (hu-mouse models). We co-design study protocols/experiments performing the ordered studies and providing comprehensive data collection, data analysis and reports.
Every day, QIAGEN serves 500,000 customers globally, all seeking insights from DNA and RNA. Delivering Sample to Insight solutions for molecular testing, we help scientists and clinicians achieve breakthroughs in life sciences research, molecular diagnostics and drug development. This is how we make improvements in life possible. In healthcare and academic institutions, and drug-discovery and forensic laboratories, QIAGEN solutions advance disease detection and treatments, enable precision medicine, and aid crime detection and human identification.
We are a target discovery and gene editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno oncology.
Our proprietary AI target discovery engine is called “Diamond.”
Diamond is AI big data science meeting target identification, dramatically compressing man years and billions of drug development dollars to develop a live drug.
Our first product is Alexis-Pro and Alexis-ISO, off-the-shelf allogenic chPD1, and iso-mesothelin CAR-T(s) for solid tumor.
Veracyte is a pioneering, global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment. Veracyte offers customized multi-omics tools and expertise to our biopharmaceutical partners, helping them advance their therapeutic discovery, development and commercialization programs.
Kibur Medical has a proprietary approach to personalized cancer therapies based on in vivo functional profiling of human tumor response to up to 20 drug and/or drug combinations simultaneously. We apply single cell, multi-omic analyses with advanced bioinformatic algorithms to gain a deep molecular understanding of drug-tumor response in pre-clinical and Phase 0 human clinical studies allowing selection of drug candidates with a high probability for clinical success and to clinically predict oncology drugs/drug combinations for individualized cancer therapies.
BioIVT is a leading provider of control and disease state samples (human/animal tissues, cells, blood, other biofluids). Combining technical expertise, exceptional customer service, and unparalleled access to biospecimens, BioIVT partners with scientists in ELEVATING SCIENCE.
Cura Diagnostics, LLC (iCura) is a fast-growing Contract Research Orgnization (CRO) and Clinical Diagnostics Laboratory, conveniently located in the tri-state area of Pennsylvania (adjacent to New Jersey and Delaware). iCura Diagnostics has focused its services on utilizing advanced diagnostic technologies such as Digital Pathology, multiplexing Immunofluorescence (IF)/Immunohistochemistry (IHC), Digital Image Analysis, Liquid Biopsy (including Circulating Tumor Cells (CTC) and ctDNA), and Genomic Services ranging from realtime PCR, digital PCR, to NGS, to provide translational research services, as well as clinical diagnostic services for oncology, metabolic disease, neurologic disorder, cardiovascular conditions, etc. The technology and services provided by iCura can be widely applied to translational research in areas such as cancer research, spatial biology, immunotherapy, and cell & gene therapy. iCura has Pennsylvania Department of Health Laboratory permit, CLIA registration, and is using CAP as its accreditation agency.
Talem Therapeutics is a biotherapeutic company and a wholly owned subsidiary of ImmunoPrecise Antibodies (IPA) that leverages IPA’s antibody discovery and development expertise combined with AI/bioinformatics to generate valuable assets (best-in-class / first-in-class) for out-licensing and co-development. Talem's experts focus on next generation antibodies from target validation through IND-Readiness (indication agnostic).